Nitrogen ( DrugBank: Nitrogen )
5 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 5 | Progressive supranuclear palsy | 1 |
| 6 | Parkinson disease | 1 |
| 17 | Multiple system atrophy | 1 |
| 211 | Hypoplastic left heart syndrome | 1 |
| 299 | Cystic fibrosis | 1 |
5. Progressive supranuclear palsy
Clinical trials : 89 / Drugs : 107 - (DrugBank : 40) / Drug target genes : 65 - Drug target pathways : 108
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-UMIN000008959 | 2012/11/01 | 16/10/2012 | Trial of molecular hydrogen water in Multiple system atrophy and Progressive supranuclear palsy | Trial of molecular hydrogen water in Multiple system atrophy and Progressive supranuclear palsy - Randomized Double-blind, Placebo-controlled trial on molecular hydrogen water in MSA and PSP | Multiple system atrophy(MSA)Progressive supranuclear palsy (PSP) | hydrogen water pseudo-water (nitrogen filling water) | Juntendo University School of Medicine, Department of Neurology | NULL | Complete: follow-up complete | 20years-old | 80years-old | Male and Female | 40 | Phase 1 | Japan |
6. Parkinson disease
Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-UMIN000010014 | 2013/02/28 | 13/02/2013 | Randomized Double-blind, Placebo-controlled multi-center trial on molecular hydrogen water in Parkinson Disease | Randomized Double-blind, Placebo-controlled multi-center trial on molecular hydrogen water in Parkinson Disease - Randomized Double-blind, Placebo-controlled trial on hydrogen water in Parkinson Disease | Parkinson's disesase | hydrogen water made by "Suisosui5.0" placebo-water (nitrogen filling water) | Juntendo University School of Medicine, Neurology | NULL | Complete: follow-up complete | 20years-old | Not applicable | Male and Female | 200 | Not selected | Japan |
17. Multiple system atrophy
Clinical trials : 119 / Drugs : 138 - (DrugBank : 44) / Drug target genes : 59 - Drug target pathways : 111
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-UMIN000008959 | 2012/11/01 | 16/10/2012 | Trial of molecular hydrogen water in Multiple system atrophy and Progressive supranuclear palsy | Trial of molecular hydrogen water in Multiple system atrophy and Progressive supranuclear palsy - Randomized Double-blind, Placebo-controlled trial on molecular hydrogen water in MSA and PSP | Multiple system atrophy(MSA)Progressive supranuclear palsy (PSP) | hydrogen water pseudo-water (nitrogen filling water) | Juntendo University School of Medicine, Department of Neurology | NULL | Complete: follow-up complete | 20years-old | 80years-old | Male and Female | 40 | Phase 1 | Japan |
211. Hypoplastic left heart syndrome
Clinical trials : 22 / Drugs : 29 - (DrugBank : 9) / Drug target genes : 5 - Drug target pathways : 14
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-UMIN000017311 | 2015/05/01 | 01/05/2015 | Hypoxia inhalation therapy for infants with pulmonary congestion caused by congenital heart disease. | Hypoxia inhalation therapy for infants with pulmonary congestion caused by congenital heart disease. - Hypoxia inhalation therapy for infants | hypoplastic left heart syndrome, coarctation of aorta, interruption of aorta, truncus arteriosus, double outlet of right ventricle (Taussig-Bing anomaly), single ventricles | Hypoxia inhalation nitrogen inhalation | Institutional Review Board of Kagoshima University | NULL | Pending | 1days-old | 365days-old | Male and Female | 30 | Not selected | Japan |
299. Cystic fibrosis
Clinical trials : 1,695 / Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00570349 (ClinicalTrials.gov) | July 2004 | 6/12/2007 | Safety and Tolerability of Inhaled Nitric Oxide in Patients With Cystic Fibrosis | Safety and Tolerability of Inhaled Nitric Oxide in Patients With Cystic Fibrosis | Cystic Fibrosis | Drug: Nitric Oxide for Inhalation;Drug: Nitrogen | Mallinckrodt | NULL | Completed | 12 Years | N/A | All | 18 | Phase 1/Phase 2 | United States |